Sibo Tian1, Jeffrey M Switchenko2, Teng Fei2, Robert H Press1, Mustafa Abugideiri1, Nabil F Saba3, Taofeek K Owonikoko3, Amy Y Chen4, Jonathan J Beitler1,3,4, Walter J Curran1, Theresa W Gillespie5, Kristin A Higgins1. 1. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 2. Department of Biostatistics & Bioinformatics, Rollins School of Public Heath, Emory University, Atlanta, Georgia. 3. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. 4. Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, Georgia. 5. Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: We compared overall survival (OS) between radiation therapy (RT) and chemoradiotherapy (CRT) in patients with anaplastic thyroid carcinoma (ATC) using a large database. METHODS: The National Cancer Data Base was queried for ATC patients diagnosed between 2004 and 2013 who received RT or CRT. Groups were balanced by propensity score matching (PSM) on nine relevant variables. OS was also examined in five paired subgroups given known patient heterogeneity. RESULTS: Of 858 total patients, 575 received CRT and 283 received RT. CRT was associated with decreased risk of death (hazard ratio [HR] 0.66, P < .001), 1-year OS 25.5% vs 14.3%. A survival advantage to CRT was seen using PSM cohorts (HR 0.75, P = .006). Those receiving definitive surgery saw the greatest benefit to CRT over RT (HR 0.65, P = .009), 1-year OS 39.6% vs 20.4%. CONCLUSIONS: CRT is associated with decreased risk of death in ATC; the magnitude of CRT vs RT benefit varied by subgroup.
BACKGROUND: We compared overall survival (OS) between radiation therapy (RT) and chemoradiotherapy (CRT) in patients with anaplastic thyroid carcinoma (ATC) using a large database. METHODS: The National Cancer Data Base was queried for ATCpatients diagnosed between 2004 and 2013 who received RT or CRT. Groups were balanced by propensity score matching (PSM) on nine relevant variables. OS was also examined in five paired subgroups given known patient heterogeneity. RESULTS: Of 858 total patients, 575 received CRT and 283 received RT. CRT was associated with decreased risk of death (hazard ratio [HR] 0.66, P < .001), 1-year OS 25.5% vs 14.3%. A survival advantage to CRT was seen using PSM cohorts (HR 0.75, P = .006). Those receiving definitive surgery saw the greatest benefit to CRT over RT (HR 0.65, P = .009), 1-year OS 39.6% vs 20.4%. CONCLUSIONS: CRT is associated with decreased risk of death in ATC; the magnitude of CRT vs RT benefit varied by subgroup.
Authors: Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-09 Impact factor: 11.908
Authors: P Siironen; J Hagström; H O Mäenpää; J Louhimo; A Heikkilä; I Heiskanen; J Arola; C Haglund Journal: Oncology Date: 2011-03-31 Impact factor: 2.935
Authors: Renaud De Crevoisier; Eric Baudin; Anne Bachelot; Sophie Leboulleux; Jean-Paul Travagli; Bernard Caillou; Martin Schlumberger Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Joseph K Salama; Daniel W Golden; Sue S Yom; Madhur Kumar Garg; Joshua Lawson; Mark W McDonald; Harry Quon; John A Ridge; Nabil Saba; Richard V Smith; Francis Worden; Anamaria Reyna Yeung; Jonathan J Beitler Journal: Oral Oncol Date: 2014-06 Impact factor: 5.337
Authors: Reshma Jagsi; Justin E Bekelman; Aileen Chen; Ronald C Chen; Karen Hoffman; Ya-Chen Tina Shih; Benjamin D Smith; James B Yu Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-01 Impact factor: 7.038